Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pazopanib vs placebo after nephrectomy in localized or locally advanced renal cell carcinoma
2010-020965-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Pazopanib arm with Placebo arm (2 arms). Primary endpoint: Disease-free survival (DFS). Started Aug 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2010-020965-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020965-26.